PA-EXONE
The ExOne Company (Nasdaq: XONE), the global leader in industrial sand and metal 3D printers using binder jetting technology, today announced the launch of its updated Quick Ship metal 3D printing services, featuring a new digital quoting tool and materials.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200624005137/en/
ExOne Quick Ship will now add the popular stainless steels 316L and 17-4PH to the list of materials offered through instant quoting, with delivery times of 10-15 business days, depending on number of units requested, part size, and other requirements.
“After two years of supplying thousands of 316L and 17-4 parts to select industrial customers, our updated Quick Ship services will now allow any customer to easily acquire and evaluate affordable single-alloy parts 3D printed with binder jetting,” said John Hartner, ExOne CEO.
A new Quick Ship online dashboard, available at www.exone.com/quickship , will allow customers to upload a qualifying digital design file for an instant quote and purchase, as well as create an account to track projects. More than 30 file types are accepted including STL and STP files.
Quick Ship parts will be 3D printed at ExOne’s metal production facility outside Pittsburgh, which has been binder jetting metal parts for more than two decades. It’s home to a fleet of more than two dozen metal 3D printers producing parts for prototype, low-volume, and serial production projects.
Quick Ship Service Represents Critical Progress
Binder jet 3D printing is a method of additive manufacturing in which an industrial printhead deposits a liquid binder onto a thin layer of powdered particles, layer by layer, until an object is formed. Parts printed in metal powders are then sintered in a furnace to fuse the particles.
In development since 1996, ExOne metal binder jet systems are capable of producing parts in more than 20 metals, ceramics and composite materials today. The technology is viewed as a disruptive and sustainable production method, largely because of its high speed, relatively low cost and material flexibility, among other benefits.
“The launch of Quick Ship services for single-alloy metals represents a key step forward in our development of metal binder jetting, and one that signifies our continued confidence in this technology,” said Rick Lucas, ExOne Chief Technology Officer and VP of New Markets. “We also have plans to expand the number of material offerings and size of printable parts in our Quick Ship services by year-end.”
Featured Quick Ship Metal 3D Printers
Quick Ship parts in 316L and 17-4PH will be 3D printed on ExOne’s Innovent+ and X1 25Pro metal 3D printing systems. Both machines feature ExOne’s exclusive Triple ACT system, an advanced compaction technology that delivers industry-leading density and repeatability in metal binder jetting. ExOne 3D printers with Triple ACT are capable of delivering sintered dimensional accuracy of +/- 2.5% on a first print run, with better results possible after additional sintering optimization.
ExOne will continue to offer its popular 316 and 420 materials infiltrated with bronze on its classic M-Flex and R2 metal 3D printing models, which have been in operation since 2013 and 2003, respectively. Infiltrated parts, which offer a variety of functionality and finish benefits, are typically shipped within 10 business days.
Other Materials Available Through Premium Quote
Metal, ceramic and composite materials not available through ExOne’s Quick Ship service will continue to be offered on a limited basis through ExOne’s Premium Quote service. Delivery times will vary based on the project details.
The full list of materials printable on ExOne 3D printing systems can be viewed at www.exone.com/metalmaterial . Materials such as M2 Tool Steel and Inconel 718 are available for quoting, and quote requests may depend on material availability.
About ExOne
ExOne is the pioneer and global leader in binder jet 3D printing technology. Since 1995, we’ve been on a mission to deliver powerful 3D printers that solve the toughest problems and enable world-changing innovations. Our 3D printing systems quickly transform powder materials — including metals, ceramics, composites and sand — into precision parts, metalcasting molds and cores, and innovative tooling solutions. Industrial customers use our technology to save time and money, reduce waste, improve their manufacturing flexibility, and deliver designs and products that were once impossible. As home to the world’s leading team of binder jetting experts, ExOne also provides specialized 3D printing services, including on-demand production of mission-critical parts, as well as engineering and design consulting. Learn more about ExOne at www.exone.com
or on Twitter at @ExOneCo. We invite you to join with us to #MakeMetalGreen™.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200624005137/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aesyra Demonstrates Significant Sleep Bruxism Reduction in Clinical Study26.1.2026 09:00:00 CET | Press release
Aesyra SA, a Swiss medtech company developing innovative digital therapeutics for dental and sleep-related disorders, today announced the successful completion of its clinical investigation evaluating the efficacy and safety of AesyBite™ Active, an intelligent oral appliance designed to treat and prevent sleep bruxism through biofeedback. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126533019/en/ AesyBite Custom smart nightguard by Aesyra SA. The clinical investigation demonstrated that AesyBite™ Active achieved a statistically significant and clinically meaningful reduction in sleep bruxism activity, exceeding the predefined performance target. Strong and robust clinical outcomes In the study (Identifier: NCT06153810), involving 26 adult patients with confirmed sleep bruxism, activation of the AesyBite Active biofeedback system resulted in a 60.6% reduction in total sleep bruxism duration per hour compared to baseline
Franklin Templeton Aligns Alternative Credit Firms Under BSP Brand26.1.2026 08:58:00 CET | Press release
Benefit Street Partners and Alcentra align under a single, refreshed BSP brand.Move reflects client demand for a specialist, integrated and global credit platform.Franklin Templeton’s alternative credit platform on track to exceed $100bn in 2026.BSP outlines further growth plans including expansion in the Middle East and Asia.New research says 51% of institutional investors will increase credit allocation in 2026.81% of institutions say a specialist focus on credit is the top attribute for performance. Franklin Templeton’s US and European alternative credit businesses, Benefit Street Partners and Alcentra, have now aligned under an updated Benefit Street Partners (BSP) brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260123270080/en/ David Manlowe, CEO of Benefit Street Partners The move is the final step in BSP and Alcentra’s integration – two pioneering alternative credit firms that Franklin Templeton acquired in 2019
Samsung Epis Holdings Reports Fourth Quarter and Fiscal Year 2025 Financial Results26.1.2026 08:00:00 CET | Press release
In its first financial results announcement after the spin-off, Samsung Bioepis recorded FY2025 revenue of KRW 1.672 trillion, highest annual revenue in its 14-year historyExcluding milestone revenue, annual sales revenue grew 28% year-over-year (YoY), recording KRW 1.626 trillion, with 101% YoY growth in operating profit to KRW 330.8 billion Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced financial results for the fourth quarter and fiscal year 2025. “We are very pleased to report strong year-to-date sales growth in our first financial results following the spin-off. Our organic growth has been driven by solid performance across our biosimilars portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are continuing to make meaningful progress in our regulatory and commercial milestones with our existing biosimilars portfolio, while strategically
Syngenta and Statkraft Sign Five-Year Virtual Power Purchase Agreement26.1.2026 08:00:00 CET | Press release
Virtual wind PPA with guarantees of origin to decarbonize Syngenta's plants in Europe Important element in carbon reduction journey for Syngenta AG Syngenta, one of the world’s biggest agricultural innovation companies, and Statkraft, a leading provider of innovative green energy solutions in Europe, have signed a virtual power purchase agreement (vPPA) covering Syngenta’s CP & Seeds operations for a period of five years. The volume amounts to 125 GWh per year and a total of 625 GWh of green electricity by the end of the contract in 2030. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260125701845/en/ Syngenta and Statkraft sign five-year virtual power purchase agreement With the vPPA, Statkraft is supporting Syngenta in advancing its sustainability strategy through the purchase of renewable energy. "This is Syngenta's first vPPA, marking a pivotal step in our decarbonization strategy," said Rachel Stenson Bugnon, Global Hea
Merz Therapeutics Submits Application to the European Medicines Agency for New Indication of XEOMIN® in Pediatric Spasticity26.1.2026 08:00:00 CET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that it has completed the regulatory submission for XEOMIN® (incobotulinumtoxinA) for the treatment of spasticity of the lower and upper limb in children and adolescents aged 2–17 years in the European Union (EU) and European Economic Area (EEA). If approved, the indication would expand access to an established botulinum neurotoxin therapy for some of the youngest and most vulnerable patients across Europe. Spasticity is a common and often debilitating condition in children and adolescents with certain neurological conditions, leading to increased muscle tone that can significantly limit movement, function and independence. One of the most common underlying causes of spasticity in children is cerebral palsy (CP), the most frequent motor disability in childhood, with spastic forms accounting for approximately 80% of all cases. In more severe cases, spasticity associated with CP can also affect spe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom